International Aids Vaccine Initiative
A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.
- Conditions
- HIV Infections
- First Posted Date
- 2013-09-09
- Last Posted Date
- 2018-01-11
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 21
- Registration Number
- NCT01937455
- Locations
- π¬π§
Surrey Clinical Research Centre, Guildford, United Kingdom
π¬π§Southampton Centre for Biomedical Research, Southampton, United Kingdom
Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers
- Conditions
- HIV Infections
- First Posted Date
- 2012-10-15
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 65
- Registration Number
- NCT01705990
- Locations
- π°πͺ
Kenya AIDS Vaccine Initiative, Nairobi, Kenya
π·πΌProject San Francisco, Kigali, Rwanda
π¬π§St. Stephen's Centre, London, United Kingdom
Safety and Immunogenicity Study of HIV-MAG Vaccine +/- IL-12 and Ad35-GRIN/ENV in HIV-uninfected Volunteers
- Conditions
- HIV Infections
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2013-09-02
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 75
- Registration Number
- NCT01496989
- Locations
- π°πͺ
Kenya AIDS Vaccine Initiative, Kangemi, Nairobi, Kenya
π·πΌProjet San Francisco, Kigali, Rwanda
πΊπ¬Uganda Virus Research Institute-IAVI, Entebbe, Uganda
A Phase IIA Trial to Evaluate the Safety and Immunogenicity of a DNA HIV-1 Vaccine Followed by an MVA HIV-1 Vaccine in HIV-uninfected Volunteers
- Conditions
- HIV Infections
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2011-06-10
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 115
- Registration Number
- NCT01371175
- Locations
- π°πͺ
KAVI (Kenya AIDS Vaccine Initiative), Nairobi, Kenya
π¬π§Guys and St. Thomas' Hospital, London, United Kingdom
Safety and Immunogenicity Study of 2 Investigational Preventive HIV Vaccines
- Conditions
- HIV Infections
- First Posted Date
- 2010-12-21
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 147
- Registration Number
- NCT01264445
- Locations
- π°πͺ
Kenya AIDS Vaccine Initiative, Nairobi, Kenya
πΊπ¬Uganda Virus Research Institute-IAVI, Entebbe, Uganda
πΊπ¬Medical Research Council, Masaka, Uganda
Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults
- Conditions
- HIV Infections
- First Posted Date
- 2010-10-06
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 218
- Registration Number
- NCT01215149
- Locations
- πΊπΈ
Brigham and Women's Hospital, Boston, Massachusetts, United States
π°πͺKenya AIDS Vaccine Initiative, Kangemi, Kenya
π·πΌProjet San Francisco, Kigali, Rwanda
A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa
- Conditions
- HIV Infections
- Interventions
- Drug: FTC/TDFDrug: Placebo
- First Posted Date
- 2009-09-03
- Last Posted Date
- 2010-08-09
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 72
- Registration Number
- NCT00971230
- Locations
- π°πͺ
Kenya Medical Research Institute, Center for Geographic Medicine Research - Coast, Kilifi, Kenya
π°πͺKenya AIDS Vaccine Initiative, University of Nairobi, Nairobi, Kenya
A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa
- Conditions
- HIV Infection
- Interventions
- Drug: FTC/TDFDrug: Placebo
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2011-08-25
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 72
- Registration Number
- NCT00931346
- Locations
- πΊπ¬
MRC-Entebbe, Entebbe, Uganda
Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine
- Conditions
- HIV Infections
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2013-02-11
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 32
- Registration Number
- NCT00902824
- Locations
- π¬π§
St Stephen's Centre Chelsea and Westminster Hospital, London, United Kingdom
Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid
- Conditions
- Human Immunodeficiency Virus InfectionsHIV Infections
- First Posted Date
- 2009-04-27
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 91
- Registration Number
- NCT00888446
- Locations
- πΏπ¦
Desmond Tutu HIV Centre Cape Town, Cape Town, South Africa
πΏπ¦Medunsa, South Africa, South Africa
πΏπ¦Perinatal HIV Research Unit, Baragwanath Hospital, Soweto, South Africa